Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

07/23/2021 | 06:45am EDT
   -- Dose deliveries for new order expected to occur from October 2021 through 
      April 2022 

NEW YORK AND MAINZ, GERMANY, July 23, 2021 -- https://www.globenewswire.com/Tracker?data=Q9DwfeUdO6j330vcMIbIKgicU-RrAouWPvojM1TBMNA-VD_EssXzR_aVkblVo-iEs_e90deDdw8rwXphQD0q3A== Pfizer Inc. (NYSE: PFE) and https://www.globenewswire.com/Tracker?data=3aDD9Pax_aUMZ-Fw72j3y6VHR6je0RV_bfG9BKaNUh4q1lIrk_d0wCYbJkIKUig-75Re06dRtitUEJcB_CAkLQ== BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its https://www.globenewswire.com/Tracker?data=fHDOYoGzYbLE2Lg69GZ706sj-VzAK2tzvBX9GC_DH7Pnyct2ey9FDNz1GGvmXC3a91OuINyGCXlT4Cwlp9hUGIHz1sQvjYYJWMYFJ56gKSLZU-q5YQ48MKjV2WTMtZq0GBxfnw09-ndz1C4Ewg42i3WF5zbr2kVcphyCLcuXWWjhLh3aPubN3qv9M2diUJnFEwhBJtH4Ul5YwZ45I0mSKDWRn7GFoSTHFUXcBorKL_7u7UrLfNvjbhcbLMXpLhRcCf61Initk0BYnKgRYZB8adtWbDARuvnusOIsOGSIBzCuGAYPXY7KJy5jYG6BQ1mMBNE6SiPU-S10GSlMAmv-IZOUe5za2fmU9fHaMivNVi9whyQbuE5YqBKiG73GFjrB existing supply agreement to 500 million. In a https://www.globenewswire.com/Tracker?data=Dn2uoD8oCLhYTIPfESY8KdgApBzEK-zckCKExRjF5k0xhOaP1FbAmUKNhgHm2mlW4p8F8L2FjC3Tku3inIksRzRLSimrb0LCCdKldI7_c1Hy3HuOf5Y7pQBaRs4AAs4UE6TLl_or4rJEFsi7pvWP-zSjtTxPkbvfupBKrhoW6FLMcozKHAwZVjHolFU0BlUg8qxkTCI_aYyu4DkCizhKx_ZzliX1YF0NxEU_sXS1Ehg= separate announcement on June 10, 2021, Pfizer and BioNTech shared plans to provide the U.S. government with 500 million doses of the companies' COVID-19 vaccine for donation to the world's poorest nations.

"As a long-term partner to the U.S. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country. Vaccines have been and will remain critical to protecting lives against this devastating disease," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "These additional doses will help the U.S. government ensure broad vaccine access into next year."

"It has been our consistent goal to supply as many doses of our COVID-19 vaccine as possible to people around the world to help bring an end to this pandemic," said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "We are honored to support the U.S. and more than 100 countries in their continuing vaccination programs."

The companies expect to deliver 110 million of the additional doses by December 31, 2021, with the remaining 90 million doses to be delivered no later than April 30, 2022. The U.S. government also has the option to acquire an updated version of the vaccine to address potential variants as well as new formulations of the vaccine, if available and authorized.

Eligible U.S. residents will continue to receive the vaccine for free, consistent with the U.S. government's commitment for free access to COVID-19 vaccines.

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for use in individuals 12 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at https://www.globenewswire.com/Tracker?data=GOo_P27dx6eV4DMUMn_usXuMPd6HI-SsVq1gmNg7AhWTluVAJNf8-Cr4tnwcSnDZTiaAtAaulXPu8JRQOSh7qY1OF8xM77Q32hi3sYTBL_Y= www.cvdvaccine-us.com.


The Pfizer-BioNTech COVID19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.


   -- Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with 
      known history of a severe allergic reaction (eg, anaphylaxis) to any 
      component of the Pfizer-BioNTech COVID-19 Vaccine 
   -- Appropriate medical treatment used to manage immediate allergic reactions 
      must be immediately available in the event an acute anaphylactic reaction 
      occurs following administration of Pfizer-BioNTech COVID-19 Vaccine 
   -- Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of 
      immediate adverse reactions according to the Centers for Disease Control 
      and Prevention guidelines ( 
   -- Reports of adverse events following use of the Pfizer-BioNTech COVID-19 
      Vaccine under EUA suggest increased risks of myocarditis and pericarditis, 
      particularly following the second dose. The decision to administer the 
      Pfizer-BioNTech COVID-19 Vaccine to an individual with a history of 
      myocarditis or pericarditis should take into account the individual's 
      clinical circumstances 
   -- Syncope (fainting) may occur in association with administration of 
      injectable vaccines, in particular in adolescents. Procedures should be 
      in place to avoid injury from fainting 
   -- Immunocompromised persons, including individuals receiving 
      immunosuppressant therapy, may have a diminished immune response to the 
      Pfizer-BioNTech COVID-19 Vaccine 
   -- The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine 
   -- In clinical studies, adverse reactions in participants 16 years of age 
      and older included pain at the injection site (84.1%), fatigue (62.9%), 
      headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), 
      fever (14.2%), injection site swelling (10.5%), injection site redness 
      (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%) 
   -- In a clinical study, adverse reactions in adolescents 12 through 15 years 
      of age included pain at the injection site (90.5%), fatigue (77.5%), 
      headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), 
      joint pain (20.2%), injection site swelling (9.2%), injection site 
      redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%) 
   -- Following administration of the Pfizer-BioNTech COVID-19 Vaccine, the 
      following have been reported outside of clinical trials: 
          -- severe allergic reactions, including anaphylaxis, and other 
             hypersensitivity reactions, diarrhea, vomiting, and pain in 
             extremity (arm) 
          -- myocarditis and pericarditis 
   -- Additional adverse reactions, some of which may be serious, may become 
      apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine 
   -- Available data on Pfizer-BioNTech COVID-19 Vaccine administered to 
      pregnant women are insufficient to inform vaccine-associated risks in 
   -- Data are not available to assess the effects of Pfizer-BioNTech COVID-19 
      Vaccine on the breastfed infant or on milk production/excretion 
   -- There are no data available on the interchangeability of the 
      Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete 
      the vaccination series. Individuals who have received one dose of 
      Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of 
      Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series 
   -- Vaccination providers must report Adverse Events in accordance with the 
      Fact Sheet to VAERS online at https://vaers.hhs.gov/reportevent.html. For 
      further assistance with reporting to VAERS call 1-800-822-7967. The 
      reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" 
      in the description section of the report 
   -- Vaccination providers should review the Fact Sheet for Information to 
      Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for 
      Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use 
   -- Before administration of Pfizer-BioNTech COVID-19 Vaccine, please see 
      Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers 
      Administering Vaccine (Vaccination Providers) including Full EUA 
      Prescribing Information available at www.cvdvaccine-us.com 

About Pfizer: Breakthroughs That Change Patients' Lives

(MORE TO FOLLOW) Dow Jones Newswires

July 23, 2021 06:45 ET (10:45 GMT)

All news about BIONTECH SE
10:38aPFIZER : FDA Sees Current COVID-19 Vaccine Protocol as Still Effective Ahead of ..
07:22aPFIZER : FDA Says Currently Authorized COVID-19 Vaccines in the US Remain Effect..
04:46aSingapore Sees Lowest Unemployment Rate Since March 2020 in Q2; Job Vacancies..
12:17aUS FDA Staff Says Waning COVID-19 Jab Efficacy Unproven, Pfizer Argues Otherw..
09/15ADRs End Mixed; BioNTech, Gol Among Companies Actively Trading
09/15Healthcare Shares Move Higher as Vaccine Boosters Remain in Focus -- Healthca..
09/15MODERNA : U.S. hopes COVID vaccine boosters will decrease not just deaths, but v..
09/15PFIZER : to Seek FDA Approval for COVID-19 Vaccine Use in Infants in November
09/15PFIZER : Mulls US Nod For COVID-19 Jab In Children As Young As Six Months Old By..
09/14UK Medicines Regulator Clears Moderna's COVID-19 Jab for Booster Program
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Sales 2021 16 863 M 19 822 M 19 822 M
Net income 2021 8 881 M 10 439 M 10 439 M
Net cash 2021 9 100 M 10 697 M 10 697 M
P/E ratio 2021 8,48x
Yield 2021 -
Capitalization 72 597 M 85 800 M 85 339 M
EV / Sales 2021 3,77x
EV / Sales 2022 3,02x
Nbr of Employees 2 500
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Last Close Price 300,58 €
Average target price 279,31 €
Spread / Average Target -7,08%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE335.78%85 800
WUXI APPTEC CO., LTD.26.24%64 886
BEIGENE, LTD.45.26%34 920